1900 Wealth Management LLC Has $528,000 Holdings in Abbott Laboratories (NYSE:ABT)

1900 Wealth Management LLC decreased its stake in Abbott Laboratories (NYSE:ABT) by 18.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,795 shares of the healthcare product maker’s stock after selling 1,096 shares during the quarter. 1900 Wealth Management LLC’s holdings in Abbott Laboratories were worth $528,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Rappaport Reiches Capital Management LLC increased its holdings in shares of Abbott Laboratories by 0.8% in the 4th quarter. Rappaport Reiches Capital Management LLC now owns 12,287 shares of the healthcare product maker’s stock worth $1,352,000 after acquiring an additional 94 shares during the period. Avion Wealth raised its holdings in shares of Abbott Laboratories by 19.4% during the fourth quarter. Avion Wealth now owns 591 shares of the healthcare product maker’s stock worth $65,000 after acquiring an additional 96 shares during the period. Renaissance Investment Group LLC boosted its holdings in shares of Abbott Laboratories by 0.7% during the 4th quarter. Renaissance Investment Group LLC now owns 14,204 shares of the healthcare product maker’s stock worth $1,563,000 after buying an additional 100 shares during the period. Drive Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 1.5% during the 4th quarter. Drive Wealth Management LLC now owns 6,712 shares of the healthcare product maker’s stock worth $739,000 after acquiring an additional 100 shares during the period. Finally, Tectonic Advisors LLC boosted its stake in shares of Abbott Laboratories by 0.7% in the 4th quarter. Tectonic Advisors LLC now owns 15,160 shares of the healthcare product maker’s stock valued at $1,669,000 after purchasing an additional 102 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now directly owns 18,760 shares in the company, valued at $2,223,060. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The disclosure for this sale can be found here. Over the last quarter, insiders sold 56,435 shares of company stock valued at $6,451,298. Company insiders own 0.47% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Raymond James upped their price target on shares of Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Citigroup raised their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada reduced their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a report on Thursday, April 18th. Barclays lowered their price target on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Evercore ISI lifted their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $121.80.

Abbott Laboratories Stock Performance

NYSE ABT traded up $0.54 on Tuesday, reaching $107.61. The stock had a trading volume of 800,429 shares, compared to its average volume of 5,687,465. The business’s 50-day moving average price is $114.08 and its 200 day moving average price is $107.90. Abbott Laboratories has a 12-month low of $89.67 and a 12-month high of $121.64. The stock has a market cap of $186.72 billion, a P/E ratio of 33.36, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.16 and a current ratio of 1.64.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The company had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. During the same quarter in the previous year, the business earned $1.03 EPS. The company’s quarterly revenue was up 2.2% compared to the same quarter last year. As a group, equities analysts expect that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 annualized dividend and a dividend yield of 2.04%. Abbott Laboratories’s payout ratio is 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.